Skip to content

Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

Prostate Cancer

This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.

null

Conditions de participation

  • Sexe:

    MALE

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Age \> 18 years.
* Able to provide informed consent.
* Histologic diagnosis of prostate adenocarcinoma.
* ECOG performance status 0-1.
* High-risk localized disease by NCCN criteria (\>cT3, Grade group \>4, or PSA \>20 ng/mL) or clinical N1 disease.
* Clinical M0 by conventional imaging (computed tomography (CT) and bone scan (BS)) and/or molecular imaging (prostate specific membrane antigen (PSMA)- positron emission tomography (PET))

Exclusion Criteria:

* Prior pelvic radiotherapy.
* Contraindications to radiotherapy

Lieu de l'étude

Princess Margaret Cancer Center
Princess Margaret Cancer Center
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Rachel Glicksman, MD

[email protected]
416-946-4483
Étude parrainée par
University Health Network, Toronto
Participants recherchés
Plus d'informations
ID de l'étude: NCT05313815